In the present study, we utilized the in vitro model based on dystrophin-deficient hiPSC-derived cardiomyocytes (hiPSC-CM) and respective isogenic controls to identify the molecular background of DMD-associated cardiomyopathy using global proteomic and transcriptomic analyses followed by validation of selected altered pathways highlighted in the obtained omics data. The gene discussed is DMD; the disease is cardiomyopathy.